ClinicaliQ Trial Snapshot
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn’s Disease — Recruiting • Phase II • Rheumatology • NCT06233461.
- Investigational agent: TAK-279, a novel therapeutic agent, is being tested for its efficacy and safety in reducing bowel inflammation specifically in patients with moderately to severely active Crohn's disease compared to placebo.
- Patient eligibility: The trial targets adult patients with documented moderately to severely active Crohn's disease, representing a clinically significant disease burden where current treatment options may be inadequate or poorly tolerated.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take…
Eligibility Snapshot
- : 1. Male or female aged 18-75 years old with diagnosis of CD for at least 30 days. In South Korea, the age requirement for adult participants is >=19 years of age. 2. Confirmed diagnosis of moderately to severely active CD assessed by SES-CD and CDAI.
- Participants must have had an inadequate response to, loss of response to, or intolerance to at least one or more conventional, biologic, or advanced therapy for CD.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.